Newer Therapies in Rheumatology
Medical Clinics of North America · 2024
DOI: 10.1016/j.mcna.2024.02.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Clinics of North America, 2024. Verfasst von Alison Bays und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA. Hauptthemen laut MEDLINE: Rheumatic Diseases, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Seven of the 11 newer medications recently or soon to be approved to treat rheumatologic diseases discussed in this article are biologic agents and reflect the current ability of science to target specific components of the immune system. The other agents are molecules that are directed against specific immune pathway targets as well. All have shown superiority to placebo and in some cases have been compared to currently accepted therapies. Safety issues are generally centered around infections due to the immune-interrupting nature of these therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA.
- Division of Rheumatology, University of Washington, 1959 Pacific Street, Box 356428, Seattle, WA 98195, USA. Electronic address: rheumdoc@uw.edu.
Zitieren
APA
Bays, A., & Gardner, G. C. (2024). Newer Therapies in Rheumatology. Medical Clinics of North America. https://doi.org/10.1016/j.mcna.2024.02.004
Vancouver
Bays A, Gardner GC. Newer Therapies in Rheumatology. Medical Clinics of North America. 2024. doi:10.1016/j.mcna.2024.02.004
BibTeX
@article{Bays2024,
author = {Bays, Alison and Gardner, Gregory C},
title = {Newer Therapies in Rheumatology},
journal = {Medical Clinics of North America},
year = {2024},
doi = {10.1016/j.mcna.2024.02.004}
}
EUVIMED